On November 14, Professor Yang Guoping’s team and Professor Lu Yao’s team from the Third Xiangya Hospital of Central South University published a high-level online paper titled “Nonselective beta-adrenoceptor blocker use and risk of Parkinson’s disease: from multiple real-world evidence” in the international authoritative journal BMC Medicine. Professor Lu Yao and Professor Yang Guoping are the co-corresponding authors, Dr. Feng Zeying and Dr. Zhao Qiuping are the co-first authors of the paper.
Hypertensive patients have a higher risk of developing Parkinson's disease in the long term. Epidemiological evidence has shown that different antihypertensive drugs may have different effects on the occurrence and development of Parkinson's disease, in addition to the blood pressure level. However, previous research findings are inconsistent and there is a lack of real-world, high-quality research. The research first found that nonselective beta-adrenoceptor blocker is associated with the occurrence of Parkinson’s disease based on the analysis of the US Food and Drug Administration (FDA) Adverse Event Reporting System. Then, the phenomenon was validated through meta-analysis of published researches and cohort analysis of large populations. The mechanisms underlying the association between these antihypertensive drugs and the risk of Parkinson's disease were further explored and validated with genomic data. The research is the first to provide high-quality evidence on the long-term risk of drug use in people with hypertension based on multidimensional real-world data and combined with multi-omics.
Professor Yang Guoping's team is committed to solving the practical problems and unmet clinical needs in clinical evaluation of drugs and precise clinical use of drugs. Relying on platforms such as the National Engineering Research Center for Individualized Diagnosis and Treatment Technology and the National-Local Joint Engineering Laboratory of Drug Clinical Evaluation Technology, and based on data science and digital intelligence technology, the team has successfully developed a number of supporting systems for precise use of drugs such as the “Geneface” platform for safe and precise use of drugs. Professor Lu Yao’s team has been engaged in multi-source data-driven clinical research for a long time, and has been selected into a number of talent programs such as the Ten Thousand Talent Program for Young Top-notch Talents led by the Organization Department of the CPC Central Committee and the Hunan Provincial Outstanding Youth Program. Their researches have been published multiple times in top international journals such as EHJ, JACC and sub-journals of Lancet. This is a joint data-driven research on adverse drug reactions conducted by Professor Yang Guoping's and Professor Lu Yao's research teams. It has been funded and supported by the National Natural Science Foundation of China, the National Key Research and Development Program of China, the Hunan Provincial Outstanding Youth Program, and the Wisdom Gathering and Talent Cultivating Program of the Third Xiangya Hospital.
(First Reviewer: Zhang Xutong, Second Reviewer: Wang Xuan, Third Reviewer: Li Yin)
Source: The Third Xiangya Hospital Author: Xiang Yuxia
Origial article link: https://news.csu.edu.cn/info/1003/157397.htm
